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INTRODUCTION
Using high performance liquid chromatography-tandem mass spectrometry to analyze venous perfusate from isolated, perfused kidneys, we discovered that intact kidneys produce and release into the extracellular compartment adenosine 2',3'-cyclic monophosphate (2',3'-cAMP) (Jackson et al., 2009; Ren et al., 2009 ), a positional isomer of the second messenger adenosine 3',5'-cyclic monophosphate (3', . In addition, we found that kidneys, both in vitro and in vivo, can metabolize 2',3'-cAMP to adenosine 2'-monophosphate (2'-AMP) plus adenosine 3'-monophosphate (3'-AMP), and that these AMPs can be further metabolized to adenosine (Jackson et al., 2009 ). More recently, we have shown the existence of 2',3'-cAMP, 2'-AMP and 3'-AMP in vivo in mice and humans (Verrier et al., 2012) .
Although our previously published studies show that exogenous 2',3'-cAMP, 2'-AMP and 3'-AMP alter vascular smooth muscle cell, endothelial cell and epithelial cell proliferation via conversion to adenosine, those experiments were performed by incubating cells in vitro for several days with these compounds (Jackson et al., 2010; Jackson et al., 2011a; Jackson et al., 2011b; Jackson and Gillespie, 2012) . Thus it is unknown whether conversion of 2',3'-cAMP, 2'-AMP or 3'-AMP to adenosine occurs rapidly enough in vivo to yield significant biological effects. To our knowledge the only in vivo study that addressed this question was published in
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8 Transonic Systems, Inc) for measurement of renal blood flow (RBF) and mesenteric blood flow (MBF) . After a one-hour stabilization period, urine was collected for 30 minutes while MABP and HR were time-averaged during this clearance period. Also, RBF and MBF were recorded at 10, 20 and 30 minutes and cardiac output was measured at 10, 20 and 30 minutes by injecting 0.15 ml of room temperature saline. A 0.2 ml blood sample was taken during the middle of the 30-minute urine collection, centrifuged and obtained for measurement of plasma creatinine. In some rats, the intravenous saline infusion (saline group) was continued, and in other rats the intravenous saline infusion was changed to either 2'-AMP, 3'-AMP, 5'-AMP, 2',3'-cAMP, 3',5'-cAMP or adenosine at 0.03 µmoles/kg/min. Each rat received only a single substance (either saline, 2'-AMP, 3'-AMP, 5'-AMP, 2',3'-cAMP, 3',5'-cAMP or adenosine; i.e., 7 groups). The infusions were continue for 40 minutes, and during the last 30 minutes of the experimental period, all measurements as described above were repeated. This procedure was then repeated with two additional 40-minute experimental periods using 0.1 and then 0.3 µmoles/kg/min of 2'-AMP, 3'-AMP, 5'-AMP, 2',3'-cAMP, 3',5'-cAMP or adenosine.
Protocol 2 (High-Dose Study). This protocol, which was performed in a separate 7 groups of rats, was the same as described for Protocol 1 (Low-Dose Study) except that the doses of 2'-AMP, 3'-AMP, 5'-AMP, 2',3'-cAMP, 3',5'-cAMP and adenosine were 1, 3 and 10 µmoles/kg/min.
9 minutes, and MABP and HR were time-averaged. Also, RBF and MBF were measured at 10, 20 and 30 minutes and CO was measured at 10, 20 and 30 minutes. Next, rats received an intravenous infusion of either 2'-AMP, 3'-AMP, 2',3'-cAMP, or adenosine (3 µmol/kg/min).
Each rat received only a single treatment (i.e., 8 groups: saline + 2'-AMP; saline + 3'-AMP; saline + 2',3'-cAMP; saline + adenosine; DPSPX + 2'-AMP; DPSPX + 3'-AMP; DPSPX + 2',3'-cAMP; and DPSPX + adenosine). The infusions were continued for 40 minutes, and measurements were repeated for the last 30 minutes of the experimental period.
Analytical Measurements. Creatinine was measured using a creatinine autoanalyzer (Creatinine Analyzer 2; Beckman Instrument, Inc., Fullerton CA) and sodium was measured by flame photometry (Model IL-943; Instrumentations Laboratory Inc., Lexington, MA) In some urine samples, 2'-AMP, 3'-AMP, 5'-AMP, 2',3'-cAMP, 3',5'-cAMP and adenosine were measure using high performance liquid chromatography-tandem mass spectrometry as previously described (Jackson et al., 2009 Figure 1 , 2',3'-cAMP, 2'-AMP, 3'-AMP, 5'-AMP and adenosine dose-dependently decreased MABP. In this regard, the threshold for reducing MABP was remarkable low (0.1 μ moles/kg/min) and the effects at 10 μ moles/kg/min were profound (60 to 70% reduction in MABP). In general, the hypotensive effects of 2'-AMP and 3'-AMP were greater compared with adenosine. Notably, 3',5'-cAMP only reduced MABP at the higher doses and then only moderately (27% at the highest dose). These findings indicate that 2',3'-cAMP, 2'-AMP and 3'-AMP are at least as effective as or more effective than adenosine as a hypotensive agent and that 3', 5'-cAMP in contrast has little or only moderate effects on arterial blood pressure.
RESULTS
Effects of Purines on MABP. As shown in
Effects of Purines on HR. 2',3'-cAMP, 2'-AMP, 3'-AMP, 5'-AMP and adenosine also dose-dependently decreased HR (Figure 2) , with 2',3'-cAMP, 2'-AMP and adenosine exhibiting a threshold effect at 0.03 μ moles/kg/min. At several concentrations, the effects of 2',3'-cAMP, 2'-AMP and 3'-AMP exceeded that of adenosine. In contrast, 3',5'-cAMP had little, if any, effect on HR. Thus, as with MABP, 2',3'-cAMP, 2'-AMP and 3'-AMP are at least as effective as or more effective than adenosine as a bradycardic agent and 3', 5'-cAMP in contrast has little effect on HR.
Effects of Purines on CO. Although variable, 2',3'-cAMP, 2'-AMP, 3'-AMP, 5'-AMP and adenosine tended to decrease CO; however, these effects reached significance only for some doses of 2',3'-cAMP, 2'-AMP and 3'-AMP; and for adenosine only at the highest dose ( Figure   3 ). As with MABP and HR, 3',5'-cAMP had little, if any, effect on CO. These data suggest that the hypotensive effects of these purines are only partially explained by decreases in CO.
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Effects of Purines on TPR and MVR. The higher doses of 2',3'-cAMP, 2'-AMP, 3'-AMP, 5'-AMP and adenosine reduced TPR, whereas 3',5'-cAMP did not (Figure 4) . The mesenteric vascular bed was particularly sensitive to the vasodilatory effects of these purines as evidence by the decreases in MVR beginning at 0.1 to 0.3 μ moles/kg/min (Figure 5 ). Once again, 3',5'-cAMP had little, if any, effect. These data suggest that systemic vasodilation importantly contributes to the hypotensive effects of these purines.
Effects of Purines on RVR.
Neither adenosine, 5'-AMP nor 3',5'-cAMP significantly altered RVR (Figure 6 ). The effects of 2',3'-cAMP, 2'-AMP and 3'-AMP were biphasic with low doses tending to decrease RVR and high doses increasing RVR, particularly 2'-AMP.
Effects of Purines on UV. 2',3'-cAMP, 2'-AMP and 3'-AMP had little effect on UV at low doses, but profoundly (in some cases 100%) decreased UV at higher doses (Figure 7) . The effects of 5'-AMP and adenosine were biphasic, with low doses increasing and high doses decreasing UV (Figure 7) . 3',5'-cAMP only slightly decreased UV at the highest dose.
Effects of Purines on GFR and Na + ER. Because of the profound suppression of UV by the higher doses of purines (Figure 7) , it was only possible to measure GFR and Na + ER with the low doses of purines (Figure 8 ). At these lower doses, adenosine and 5'-AMP had little effect on GFR and Na + ER. 2',3'-cAMP did not affect GFR, but decreased Na + ER; whereas 2'-AMP and 3'-AMP suppressed both GFR and Na + ER. In contrast, 3',5'-cAMP did not affect GFR and increased Na + ER. 
Effects of Purines on
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The present study unequivocally demonstrates the concepts that 2',3'-cAMP, 2'-AMP and 3'-AMP are biologically active in vivo and that their biological activity is mediated by rapid conversion to adenosine. These conclusions are based on our observations that 2',3'-cAMP, 2'-AMP and 3'-AMP dose-dependently and profoundly reduce MABP, HR, TPR and MVR with efficacies and potencies equal to or greater than those for adenosine and 5'-AMP; and blockade of adenosine receptors with DPSPX attenuates the effects of 2',3'-cAMP, 2'-AMP and 3'-AMP.
These findings are important for at least two reasons. First, this settles the issue once and for all that 2',3'-cAMP, 2'-AMP and 3'-AMP in vivo are extremely rapidly converted to adenosine in the cardiovascular system. Second, this indicates that the enzymes that metabolize these compounds to adenosine are richly expressed in vivo, which supports the concept that these are indeed important naturally-occurring purines.
It is important to note that both 2'-AMP and 3'-AMP seem to be more potent than even adenosine with respect to affecting cardiovascular parameters. Likely, 2'-AMP and 3'-AMP are a better adenosine "delivery system" because they represent an adenosine prodrug that unlike adenosine is not subjected to the extremely rapid adenosine clearance mechanisms. Thus more 2'-AMP and 3'-AMP may reach the site of action; whereas adenosine is rapidly transported into red blood cells and metabolized.
The present results are also important because they suggest a novel therapeutic opportunity using 2',3'-cAMP. Past studies suggest that adenosine would be useful for producing controlled hypotension in surgical patients in whom a temporary reduction in blood pressure is required (Sollevi et al., 1984) . Our studies show that 2',3'-cAMP can, like adenosine, produce rapid onset hypotension. However, unlike adenosine, 2',3'-cAMP increases urinary levels of adenosine. Since adenosine in the urinary compartment is renoprotective (Okusa et al., 1999; Lee and Emala, 2000; Okusa et al., 2000; Okusa et al., 2001; Lee and Emala, 2002; Okusa, 2002; Day et al., 2005; Grenz et al., 2007a; Grenz et al., 2007b; Lee et al., 2007; Grenz et al., 2008; Kim et al., 2009; Bauerle et al., 2011; Grenz et al., 2012) , 2',3'-cAMP could be a drug that allows for controlled hypotension while delivering renoprotective adenosine to the renal tubules.
Moreover, a study in perfused canine coronary arteries shows that 2',3'-cAMP does not affect coronary vascular tone (Nakane and Chiba, 1993) , suggesting that the conversion of 2',3'-cAMP to adenosine in the coronary circulation is minimal. Thus 2',3'-cAMP might be useful for controlled hypotension without causing coronary steal in patients with coronary vascular disease.
Finally, if 2',3'-cAMP is not converted to adenosine in the carotid body chemoreceptors, adverse effects of adenosine related to stimulation of chemoreceptors could be avoided. Taken together, our present findings indicate that 2',3'-cAMP should be investigated for utility as an agent to produce controlled hypotension.
By engaging A 1 , A 2A and A 2B receptors, adenosine protects the kidneys from ischemia/reperfusion injury as well as other forms of acute kidney injury (AKI) (Okusa et al., 1999; Lee and Emala, 2000; Okusa et al., 2000; Okusa et al., 2001; Lee and Emala, 2002; Okusa, 2002; Day et al., 2005; Grenz et al., 2007a; Grenz et al., 2007b; Lee et al., 2007; Grenz et al., 2008; Kim et al., 2009; Bauerle et al., 2011; Grenz et al., 2012) . However, adenosine and adenosine receptor agonists exert systemic effects (e.g., hypotension and bradycardia) that likely is that intravenous 3',5'-cAMP increases urinary adenosine excretion more so than does an equivalent dose of adenosine, 5'-AMP, 3'-AMP or 2'-AMP. But unlike these other compounds, 3',5'-cAMP has little, if any, hemodynamic or cardiac effects. It appears, therefore, that the ecto-phosphodiesterase that converts 3',5'-cAMP to adenosine is more highly expressed in the kidneys compared to other tissues and organ systems, thus allowing for 3',5'-cAMP to increase renal adenosine levels without raising system levels that would stimulate extrarenal receptors.
Although 2',3'-cAMP and 3',5'-cAMP similarly increase urinary adenosine, 2',3'-cAMP causes hypotension, suggesting that the ecto-phosphodiesterase that metabolizes 2',3'-cAMP to 2'-AMP and 3'-AMP are more ubiquitously expressed. It is conceivable, therefore, that 3',5'-cAMP could be used to selectively increase adenosine levels in the kidney to prevent or treat AKI without lowering renal perfusion pressure.
This article has not been copyedited and formatted. The final version may differ from this version. summarize the results of the low-dose and high-dose studies, respectively. In both studies, a vehicle/time control group (saline) was included. In the low-dose study, basal values for MVR were 11 ± 1, 10 ± 1, 10 ± 1, 11 ± 1, 10 ± 2, 9 ± 1, and 10 ± 2 mm Hg/(ml/min) for the saline, 2',3'-cAMP, 2'-AMP, 3'-AMP, 5'-AMP, adenosine and 3',5'-cAMP groups, respectively. The basal values in the high-dose study were 10 ± 2, 15 ± 2, 14 ± 2, 12 ± 1, 15 ± 2, 9 ± 1 and 12 ± 1 mm Hg/(ml/min), for the saline, 2',3'-cAMP, 2'-AMP, 3'-AMP, 5'-AMP, adenosine and 3',5'-cAMP groups, respectively. Values are means ± SEM for the indicate number of animals (n).
The letters "a" and "b" indicate p<0.05 (Fisher's LSD test) compared with the saline and adenosine groups, respectively. in the high-dose study were 16 ± 2, 16 ± 1, 14 ± 2, 15 ± 2, 15 ± 2, 12 ± 2 and 15 ± 1 mm Hg/(ml/min), for the saline, 2',3'-cAMP, 2'-AMP, 3'-AMP, 5'-AMP, adenosine and 3',5'-cAMP groups, respectively. Values are means ± SEM for the indicate number of animals (n).
The letters "a" and "b" indicate p<0.05 (Fisher's LSD test) compared with the saline and adenosine groups, respectively. 
n=6-7 n=4
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